With CBER Director Prasad's Resignation and Szarama's Appointment, the Regulatory Fate of uniQure's AMT-130 and Sarepta's Elevidys Remains in Focus
Sudden Departure of CBER Director and the Emergence of Interim Leadership
Vinay Prasad, the director of CBER (Center for Biologics Evaluation and Research), officially resigned at the end of April 2026, and Katherine Szarama, the deputy director, was appointed as the interim director. This change in leadership at CBER, which holds final approval authority for advanced biologics such as vaccines and gene therapies, will immediately impact new drug approval timelines. This transition is seen as a swift move by the FDA to ensure administrative continuity amidst a rapidly changing regulatory landscape. If the interim period is prolonged, there is a possibility that the review criteria may fluctuate depending on the disposition of the next permanent director. Marty Makary, the FDA Commissioner, has pledged to announce the permanent director within a few weeks, but the industry remains on edge.
Leadership Change Stemming from Regulatory Conflicts with Sarepta and uniQure
The tenure of the former director, Prasad, can be summarized as a period of significant regulatory conflicts and discord with the biopharmaceutical industry. Notably, in the summer of 2025, he was temporarily relieved of his duties due to internal disagreements within the agency regarding the approval scope of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for Duchenne Muscular Dystrophy (DMD) developed by Sarepta Therapeutics (SRPT). More recently, he clashed with uniQure (QURE) by rejecting the company's application for accelerated approval of AMT-130, a microRNA-based gene therapy for Huntington's Disease (HD) that aims to suppress HTT gene expression. The former director insisted on a randomized, placebo-controlled Phase 3 trial, leading to heated debates with the company.
Changes in the Review Process Under the New Interim Leadership
The newly appointed interim director, Katherine Szarama, has administrative and analytical experience from ARPA-H (Advanced Research Projects Agency for Health) and CMS (Centers for Medicare & Medicaid Services). Due to this background, she is considered a suitable candidate to maintain consistency in regulatory administration and prevent delays in clinical reviews. Nevertheless, biotechs focused on rare diseases, such as uniQure, hope that the Szarama interim leadership will ease the existing rigid approach. Companies that have had their applications for accelerated approval based on external control groups rejected are likely to seek reconsideration during this transitional period, but significant changes to clinical trials may be limited until the permanent director is appointed.
Medium- to Long-Term Impact on the Gene Therapy Market and Investment Sentiment
The changes in CBER's decision-making will significantly impact the overall valuation of the global rare disease gene therapy market. By 2030, the DMD therapy market is expected to grow to $3 billion annually, and the HD therapy market is expected to exceed $1 billion annually. Given the high cost of gene therapies, FDA approval is a critical factor in determining the success of venture capital (VC) exits. Overly stringent requirements for clinical trial design can lead to significant clinical costs and funding failures for biotechs. Therefore, investors should closely monitor the changes in the regulatory stance under the Szarama interim leadership.
The appointment of Szarama as interim director of the FDA's CBER introduces uncertainty into the $3 billion Duchenne Muscular Dystrophy (DMD) and $1 billion Huntington's Disease (HD) gene therapy markets. Investors need to hedge against the risk of stricter regulations, as seen in Sarepta's (SRPT) accelerated approval of Elevidys or uniQure's (QURE) AMT-130 (Phase 1/2 trial) for Huntington's Disease, which was rejected due to limitations of a single-arm control group and required a Phase 3 trial with a placebo control group. From a research perspective, the insistence on difficult-to-implement control group designs, such as placebo-controlled trials, will serve as a benchmark for future guidelines for the development of next-generation therapies. Beyond preventing short-term review delays, the long-term success of companies like Pfizer (PFE) and the timeline for VC exits will depend on the new permanent director's approach to accelerated approvals. Industry stakeholders need to proactively address changes in CBER's requirements for accelerated approval and post-market surveillance regulations.